Neurology

Back to articles

Rasagiline may slow progression of Parkinson’s disease

KEY POINT

A large, delayed-start, designed trial in 1,176 patients with early-stage Parkinson’s disease suggests that early initiation of rasagiline (Azilect—Teva) 1 mg/d may slow disease progression. Some experts are skeptical, however, because the clinical significance of improvements between early and delayed initiation appeared modest, and early initiation of 2 mg/d, a nonapproved dose, did not result in statistically significant findings.

SOURCES

Olanow CW et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268–78. 

LeWitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology. 2009;72:1352–7.